Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Furosemide + prednisolone is a combination of two pharmaceutical drugs, each with distinct mechanisms and indications. Furosemide is a loop diuretic that acts on the kidneys to increase the excretion of sodium, chloride, and water, thereby reducing fluid overload in conditions such as heart failure, liver cirrhosis, renal disease (including nephrotic syndrome), and hypertension. Prednisolone is a synthetic glucocorticoid corticosteroid with potent anti-inflammatory and immunosuppressive properties; it binds to the glucocorticoid receptor to modulate gene expression and suppress pro-inflammatory pathways. This combination may be used in clinical scenarios where both diuresis (fluid removal) and anti-inflammatory or immunosuppressive effects are required—such as severe edema associated with inflammatory or autoimmune diseases—but must be used cautiously due to an increased risk of hypokalemia (low potassium) from additive effects on electrolyte balance[5][1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on furosemide + prednisolone.